Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Coherus Oncology, Inc. (CHRS)

Coherus Oncology sets up up to $50.0 million at-the-market stock sale program with Leerink

Neutral Impact 3 of 5 financing Written later

Coherus Oncology entered an at-the-market sales agreement with Leerink Partners allowing it to sell up to $50.0 million of common stock from time to time, at its discretion. The company is not obligated to sell any shares, and it will pay the agent a commission of up to 3.0% of gross proceeds, so the program could dilute existing holders if used.

Key points

  • Sales Agreement with Leerink Partners LLC dated August 28, 2026, covering up to $50.0 million in common stock
  • Agent commission of up to 3.0% of gross proceeds from each sale
  • Shares offered under Form S-3 shelf registration declared effective December 8, 2025
  • Net proceeds intended for general corporate purposes, including working capital

The filing

CompanyCoherus Oncology, Inc. (CHRS)
Form8-K, current report
Filed with the SECAug 28, 2026, 5:11 PM ET
Accession number0001104659-26-103316

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.